Polymeric nanoparticles for pulmonary protein and DNA delivery

Jyothi U. Menon, Priya Ravikumar, Amruta Pise, Dipendra Gyawali, Connie C W Hsia, Kytai T. Nguyen

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Polymeric nanoparticles (NPs) are promising carriers of biological agents to the lung due to advantages including biocompatibility, ease of surface modification, localized action and reduced systemic toxicity. However, there have been no studies extensively characterizing and comparing the behavior of polymeric NPs for pulmonary protein/DNA delivery both in vitro and in vitro. We screened six polymeric NPs: gelatin, chitosan, alginate, poly(lactic-co- glycolic) acid (PLGA), PLGA-chitosan and PLGA-poly(ethylene glycol) (PEG), for inhalational protein/DNA delivery. All NPs except PLGA-PEG and alginate were <300 nm in size with a bi-phasic core compound release profile. Gelatin, PLGA NPs and PLGA-PEG NPs remained stable in deionized water, serum, saline and simulated lung fluid (Gamble's solution) over 5 days. PLGA-based NPs and natural polymer NPs exhibited the highest cytocompatibility and dose-dependent in vitro uptake, respectively, by human alveolar type-1 epithelial cells. Based on these profiles, gelatin and PLGA NPs were used to encapsulate plasmid DNA encoding yellow fluorescent protein (YFP) or rhodamine-conjugated erythropoietin (EPO) for inhalational delivery to rats. Following a single inhalation, widespread pulmonary EPO distribution persisted for up to 10 days while increasing YFP expression was observed for at least 7 days for both NPs. The overall results support both PLGA and gelatin NPs as promising carriers for pulmonary protein/DNA delivery.

Original languageEnglish (US)
Pages (from-to)2643-2652
Number of pages10
JournalActa Biomaterialia
Volume10
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Nanoparticles
DNA
Proteins
Lung
Acids
Gelatin
Polyethylene glycols
Alginate
Chitosan
Erythropoietin
Natural polymers
Alveolar Epithelial Cells
polylactic acid-polyglycolic acid copolymer
Milk
Rhodamines
Ethylene Glycol
Deionized water
Biological Factors
Biocompatibility
Inhalation

Keywords

  • DNA
  • Nanoparticles
  • Nebulization
  • Protein
  • Pulmonary

ASJC Scopus subject areas

  • Biomaterials
  • Biomedical Engineering
  • Biotechnology
  • Biochemistry
  • Molecular Biology
  • Medicine(all)

Cite this

Menon, J. U., Ravikumar, P., Pise, A., Gyawali, D., Hsia, C. C. W., & Nguyen, K. T. (2014). Polymeric nanoparticles for pulmonary protein and DNA delivery. Acta Biomaterialia, 10(6), 2643-2652. https://doi.org/10.1016/j.actbio.2014.01.033

Polymeric nanoparticles for pulmonary protein and DNA delivery. / Menon, Jyothi U.; Ravikumar, Priya; Pise, Amruta; Gyawali, Dipendra; Hsia, Connie C W; Nguyen, Kytai T.

In: Acta Biomaterialia, Vol. 10, No. 6, 2014, p. 2643-2652.

Research output: Contribution to journalArticle

Menon, JU, Ravikumar, P, Pise, A, Gyawali, D, Hsia, CCW & Nguyen, KT 2014, 'Polymeric nanoparticles for pulmonary protein and DNA delivery', Acta Biomaterialia, vol. 10, no. 6, pp. 2643-2652. https://doi.org/10.1016/j.actbio.2014.01.033
Menon, Jyothi U. ; Ravikumar, Priya ; Pise, Amruta ; Gyawali, Dipendra ; Hsia, Connie C W ; Nguyen, Kytai T. / Polymeric nanoparticles for pulmonary protein and DNA delivery. In: Acta Biomaterialia. 2014 ; Vol. 10, No. 6. pp. 2643-2652.
@article{32c46b7e178a4d33aa13c11b8969ddb7,
title = "Polymeric nanoparticles for pulmonary protein and DNA delivery",
abstract = "Polymeric nanoparticles (NPs) are promising carriers of biological agents to the lung due to advantages including biocompatibility, ease of surface modification, localized action and reduced systemic toxicity. However, there have been no studies extensively characterizing and comparing the behavior of polymeric NPs for pulmonary protein/DNA delivery both in vitro and in vitro. We screened six polymeric NPs: gelatin, chitosan, alginate, poly(lactic-co- glycolic) acid (PLGA), PLGA-chitosan and PLGA-poly(ethylene glycol) (PEG), for inhalational protein/DNA delivery. All NPs except PLGA-PEG and alginate were <300 nm in size with a bi-phasic core compound release profile. Gelatin, PLGA NPs and PLGA-PEG NPs remained stable in deionized water, serum, saline and simulated lung fluid (Gamble's solution) over 5 days. PLGA-based NPs and natural polymer NPs exhibited the highest cytocompatibility and dose-dependent in vitro uptake, respectively, by human alveolar type-1 epithelial cells. Based on these profiles, gelatin and PLGA NPs were used to encapsulate plasmid DNA encoding yellow fluorescent protein (YFP) or rhodamine-conjugated erythropoietin (EPO) for inhalational delivery to rats. Following a single inhalation, widespread pulmonary EPO distribution persisted for up to 10 days while increasing YFP expression was observed for at least 7 days for both NPs. The overall results support both PLGA and gelatin NPs as promising carriers for pulmonary protein/DNA delivery.",
keywords = "DNA, Nanoparticles, Nebulization, Protein, Pulmonary",
author = "Menon, {Jyothi U.} and Priya Ravikumar and Amruta Pise and Dipendra Gyawali and Hsia, {Connie C W} and Nguyen, {Kytai T.}",
year = "2014",
doi = "10.1016/j.actbio.2014.01.033",
language = "English (US)",
volume = "10",
pages = "2643--2652",
journal = "Acta Biomaterialia",
issn = "1742-7061",
publisher = "Elsevier BV",
number = "6",

}

TY - JOUR

T1 - Polymeric nanoparticles for pulmonary protein and DNA delivery

AU - Menon, Jyothi U.

AU - Ravikumar, Priya

AU - Pise, Amruta

AU - Gyawali, Dipendra

AU - Hsia, Connie C W

AU - Nguyen, Kytai T.

PY - 2014

Y1 - 2014

N2 - Polymeric nanoparticles (NPs) are promising carriers of biological agents to the lung due to advantages including biocompatibility, ease of surface modification, localized action and reduced systemic toxicity. However, there have been no studies extensively characterizing and comparing the behavior of polymeric NPs for pulmonary protein/DNA delivery both in vitro and in vitro. We screened six polymeric NPs: gelatin, chitosan, alginate, poly(lactic-co- glycolic) acid (PLGA), PLGA-chitosan and PLGA-poly(ethylene glycol) (PEG), for inhalational protein/DNA delivery. All NPs except PLGA-PEG and alginate were <300 nm in size with a bi-phasic core compound release profile. Gelatin, PLGA NPs and PLGA-PEG NPs remained stable in deionized water, serum, saline and simulated lung fluid (Gamble's solution) over 5 days. PLGA-based NPs and natural polymer NPs exhibited the highest cytocompatibility and dose-dependent in vitro uptake, respectively, by human alveolar type-1 epithelial cells. Based on these profiles, gelatin and PLGA NPs were used to encapsulate plasmid DNA encoding yellow fluorescent protein (YFP) or rhodamine-conjugated erythropoietin (EPO) for inhalational delivery to rats. Following a single inhalation, widespread pulmonary EPO distribution persisted for up to 10 days while increasing YFP expression was observed for at least 7 days for both NPs. The overall results support both PLGA and gelatin NPs as promising carriers for pulmonary protein/DNA delivery.

AB - Polymeric nanoparticles (NPs) are promising carriers of biological agents to the lung due to advantages including biocompatibility, ease of surface modification, localized action and reduced systemic toxicity. However, there have been no studies extensively characterizing and comparing the behavior of polymeric NPs for pulmonary protein/DNA delivery both in vitro and in vitro. We screened six polymeric NPs: gelatin, chitosan, alginate, poly(lactic-co- glycolic) acid (PLGA), PLGA-chitosan and PLGA-poly(ethylene glycol) (PEG), for inhalational protein/DNA delivery. All NPs except PLGA-PEG and alginate were <300 nm in size with a bi-phasic core compound release profile. Gelatin, PLGA NPs and PLGA-PEG NPs remained stable in deionized water, serum, saline and simulated lung fluid (Gamble's solution) over 5 days. PLGA-based NPs and natural polymer NPs exhibited the highest cytocompatibility and dose-dependent in vitro uptake, respectively, by human alveolar type-1 epithelial cells. Based on these profiles, gelatin and PLGA NPs were used to encapsulate plasmid DNA encoding yellow fluorescent protein (YFP) or rhodamine-conjugated erythropoietin (EPO) for inhalational delivery to rats. Following a single inhalation, widespread pulmonary EPO distribution persisted for up to 10 days while increasing YFP expression was observed for at least 7 days for both NPs. The overall results support both PLGA and gelatin NPs as promising carriers for pulmonary protein/DNA delivery.

KW - DNA

KW - Nanoparticles

KW - Nebulization

KW - Protein

KW - Pulmonary

UR - http://www.scopus.com/inward/record.url?scp=84899660553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899660553&partnerID=8YFLogxK

U2 - 10.1016/j.actbio.2014.01.033

DO - 10.1016/j.actbio.2014.01.033

M3 - Article

VL - 10

SP - 2643

EP - 2652

JO - Acta Biomaterialia

JF - Acta Biomaterialia

SN - 1742-7061

IS - 6

ER -